抗血栓治疗改善社区获得性肺炎的临床并发症 (ATTACC-CAP)
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).
研究概览
详细说明
The global incidence of hospitalization due to CAP is high and associated with substantive morbidity and mortality. Thrombotic complications - including venous, arterial, and possibly microvascular - occur commonly in hospitalized patients across many etiologies of CAP. Poor outcomes may be mediated by both inflammatory and thrombotic processes leading to respiratory, cardiac, and other end organ dysfunction. There are currently no established therapies that modify the potentially maladaptive immunothrombosis pathway in CAP.
Therapeutic-dose anticoagulation with heparin reduces disease progression and mortality in non-critically ill patients hospitalized with COVID-19 with an acceptable safety profile. COVID-19 shares pathogenic features, including activation of the inflammatory and coagulation cascades, with other pneumonias. Whether therapeutic-dose heparin confers similar clinical benefits in non-COVID-19 CAP is unknown.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Chantale Pineau
- 电话号码:2042353223
- 邮箱:attacc.cap@umanitoba.ca
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T2N 2T9
- 招聘中
- Foothills Medical Centre - Alberta Health Services
-
接触:
- Deepa Suryanarayan, MD
- 电话号码:4039448167
- 邮箱:dsuryana@ucalgary.ca
-
首席研究员:
- Deepa Suryanarayan, MD
-
Grande Prairie、Alberta、加拿大、T8V 4B1
- 尚未招聘
- Grand Prairie Regional Hospital
-
接触:
- Tafi Madzimure, MD
-
首席研究员:
- Tafi Madzimure, MD
-
-
British Columbia
-
Nanaimo、British Columbia、加拿大
- 招聘中
- Nanaimo Regional General Hospital
-
接触:
- Alistair Teale, MD
-
首席研究员:
- Alistair Teale, MD
-
Penticton、British Columbia、加拿大
- 尚未招聘
- Penticton Regional Hospital
-
接触:
- Teresa Rodriguez, MD
-
Vancouver、British Columbia、加拿大、V5Z 1M9
- 招聘中
- Vancouver General Hospital
-
首席研究员:
- Ted Steiner, MD
-
接触:
- Ted Steiner, MD
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大
- 招聘中
- St. Boniface General Hospital
-
接触:
- Vi Dao, MD
-
首席研究员:
- Terry Wuerz, MD
-
首席研究员:
- Vi Dao, MD
-
Winnipeg、Manitoba、加拿大、R3A 1R9
- 招聘中
- Health Sciences Center Winnipeg
-
接触:
- Brett Houstin, MD
-
Winnipeg、Manitoba、加拿大
- 招聘中
- Grace General Hospital
-
接触:
- Sylvain Lother, MD
- 邮箱:sylvain.lother@umanitoba.ca
-
首席研究员:
- Sylvain Lother, MD
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、加拿大、A1C 5S7
- 招聘中
- Memorial University
-
接触:
- Peter Daley, MD
-
首席研究员:
- Peter Daley, MD
-
-
Ontario
-
Greater Sudbury、Ontario、加拿大、P3E 2H3
- 招聘中
- Health Sciences North Research Institute
-
接触:
- Pandma Puranam, MD
-
首席研究员:
- Pandma Puranam, MD
-
Greater Sudbury、Ontario、加拿大
- 招聘中
- Health Sciences North ResearchInstitute (HSNRI)
-
接触:
- Pandma Puranam, MD
-
Hamilton、Ontario、加拿大
- 招聘中
- Hamilton Health Sciences
-
接触:
- Alison Fox-Robichaud, MD
-
首席研究员:
- Alison Fox-Robichaud, MD
-
Hamilton、Ontario、加拿大
- 招聘中
- Hamilton Health Sciences - Juravinski
-
首席研究员:
- Dominik Mertz, MD
-
首席研究员:
- Bram Rochwerg, MD
-
接触:
- Bram Rochwerg, MD
-
Markham、Ontario、加拿大、L3P 7P3
- 招聘中
- Markham Stouffville Hospital
-
首席研究员:
- Paul Lee, MD
-
接触:
- Paul Lee, MD
-
首席研究员:
- Janet Nguyen, MD
-
Ottawa、Ontario、加拿大
- 招聘中
- The Ottawa Hospital
-
接触:
- Lana Castellucci, MD
-
Ottawa、Ontario、加拿大
- 招聘中
- Hôpital Montfort
-
接触:
- Marc Carrier, MD
-
Saint Catherines、Ontario、加拿大、L2S 0A9
- 招聘中
- Niagara Health System - St Catharines Site
-
接触:
- Aidan Findlater, MD
- 邮箱:Aidan.Findlater@niagarahealth.on.ca
-
首席研究员:
- Aidan Findlater, MD
-
Toronto、Ontario、加拿大、M4N 3M5
- 招聘中
- Sunnybrook Health Sciences Centre
-
接触:
- Jonathan Zipursky, MD
-
首席研究员:
- Jonathan Zipursky, MD
-
Toronto、Ontario、加拿大
- 尚未招聘
- St. Michael's Hospital
-
接触:
- Michael Colacci, MD
-
-
Quebec
-
Montreal、Quebec、加拿大
- 招聘中
- Jewish General Hospital
-
接触:
- Susan Khan, MD
-
接触:
- Vicky Tagalakis, MD
-
Montreal、Quebec、加拿大、H4A3J1
- 招聘中
- McGill University Health Centre
-
接触:
- Emily Gibson McDonald, MD, MSc
-
Montreal、Quebec、加拿大
- 招聘中
- Centre Hospitalier de l'université de Montréal (CHUM)
-
接触:
- Emmanuelle Duceppe, MD
-
Québec、Quebec、加拿大
- 招聘中
- CHU de Quebec-University Laval
-
接触:
- Alexis Turgeon, MD, MSc
-
Québec、Quebec、加拿大
- 招聘中
- Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
-
接触:
- Francois Lallouche, MD
-
Sherbrooke、Quebec、加拿大
- 招聘中
- Centre Hospitalier Universitaire de Sherbrooke
-
首席研究员:
- Francois Lamontagne, MD
-
接触:
- Francois Lamontagne, MD
-
-
Saskatchewan
-
Regina、Saskatchewan、加拿大、S4P 0W5
- 招聘中
- Regina General Hospital
-
首席研究员:
- Payam Dehghani, MD
-
接触:
- Payam Dehghani, MD
-
Saskatoon、Saskatchewan、加拿大
- 尚未招聘
- University of Saskatchewan
-
接触:
- Geroffrey Shumailak, MD
-
-
-
-
Mexico City
-
Mexico City、Mexico City、墨西哥
- 招聘中
- Hospital General Regional 1. Carlos MacGregor Sánchez Navarro
-
-
-
-
Espírito Santo
-
Serra、Espírito Santo、巴西、29166-828
- 招聘中
- Hospital Estadual Dr. Jayme Santos Neves
-
接触:
- Marcus Matos, MD
-
首席研究员:
- Marcus Matos, MD
-
Vila Velha、Espírito Santo、巴西
- 招聘中
- Hospital Evangelico de Vila Velha
-
接触:
- Joao Moraes Junior, MD
-
首席研究员:
- Joao Moraes Junior, MD
-
首席研究员:
- Guiherme Fonseca, MD
-
-
Estado de Bahia
-
Itabuna、Estado de Bahia、巴西
- 完全的
- Santa Casa de Misericordia de Itabuna
-
-
Federal District
-
Brasília、Federal District、巴西
- 完全的
- Hospital Brasilia
-
Brasília、Federal District、巴西
- 完全的
- Instituto de Cardiologia e Transplantes do Distrito Federal
-
-
Goiás
-
Goiânia、Goiás、巴西
- 招聘中
- Hospital de Messejana Dr. Carlos Alberto Studart Gomes
-
接触:
- Sandra Nivea dos Reis Saraiva, MD
-
首席研究员:
- Sandra Falcao, MD
-
Goiânia、Goiás、巴西
- 招聘中
- Hospital Ruy Azeredo
-
接触:
- Rafael Bastos, MD
-
首席研究员:
- Rafael Bastos, MD
-
Goiânia、Goiás、巴西
- 招聘中
- Instituto Goiano de Oncologia e Hematologia - INGOH
-
接触:
- Mayler Santos, MD
-
首席研究员:
- Mayler Santos, MD
-
-
Mato Grosso do Sul
-
Campo Grande、Mato Grosso do Sul、巴西
- 招聘中
- Hospital São Julião
-
接触:
- Maurício Pompílio Pompílio, MD
-
Campo Grande、Mato Grosso do Sul、巴西
- 招聘中
- Santa Casa de Campo Grande
-
接触:
- Eduardo Calvoso, MD
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、巴西
- 完全的
- Hospital Felicio Rocho
-
Belo Horizonte、Minas Gerais、巴西
- 完全的
- NUPEC-Orizonti
-
Belo Horizonte、Minas Gerais、巴西
- 招聘中
- Santa Casa de Misericórdia de Belo Horizonte
-
接触:
- Claudio Dornas, MD
-
Uberaba、Minas Gerais、巴西
- 招聘中
- Hospital das Clínicas da Universidade Federal do Triângulo Mineiro
-
-
Paraná
-
Campo Largo、Paraná、巴西、83606-177
- 招聘中
- Hospital do Rocio
-
接触:
- CESAR DUSILEK, MD
-
Curitiba、Paraná、巴西
- 招聘中
- Hospital Santa Cruz
-
接触:
- Marcelo Carneiro, MD
-
首席研究员:
- Marcelo Carneiro, MD
-
Curitiba、Paraná、巴西
- 完全的
- PUCPR
-
-
Rio Grande do Sul
-
Lajeado、Rio Grande do Sul、巴西
- 招聘中
- Hospital Bruno Born
-
接触:
- Lucas Mallmann, MD
-
首席研究员:
- Lucas Mallmann, MD
-
Passo Fundo、Rio Grande do Sul、巴西
- 招聘中
- Hospital Sao Vicente de Paulo
-
接触:
- Alexandre Tognon, MD
-
首席研究员:
- Alexandre Tognon
-
Porto Alegre、Rio Grande do Sul、巴西
- 招聘中
- Hospital de Clínicas de Porto Alegre
-
接触:
- Paulo Dalcin, MD
-
首席研究员:
- Paulo Dalcin, MD
-
Santa Maria、Rio Grande do Sul、巴西
- 完全的
- Hospital Universitario de Santa Maria
-
-
Rio de Janeiro
-
Rio de Janeiro、Rio de Janeiro、巴西
- 招聘中
- Hospital Clementino Fraga Filho - UFRJ
-
接触:
- Fernanda Mello
-
-
Santa Catarina
-
Criciúma、Santa Catarina、巴西
- 招聘中
- Hospital Sao Jose
-
接触:
- Felipe Pizzol, MD
-
首席研究员:
- Felipe Pizzol, MD
-
-
South Carolina
-
São José、South Carolina、巴西
- 完全的
- Hospital Regional Homero Miranda Gomes
-
-
São Paulo
-
Botucatu、São Paulo、巴西
- 招聘中
- UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu
-
接触:
- Suzana Erico Tanni, MD
-
首席研究员:
- Suzana Erico Tanni, MD
-
Bragança Paulista、São Paulo、巴西
- 招聘中
- Hospital Universitario Sao Francisco na Providencia na Deus
-
接触:
- Gustavo Mamprin, MD
-
首席研究员:
- Gustavo Mamprin, MD
-
Campinas、São Paulo、巴西
- 招聘中
- IPECC
-
接触:
- Jose Francisco Kerr Saraiva, MD
-
首席研究员:
- Jose Francisco Kerr Saraiva, MD
-
Campinas、São Paulo、巴西、13083-190
- 招聘中
- Fundação Centro Médico de Campinas
-
接触:
- Otavio Coelho, MD
-
首席研究员:
- Otavio Coelho, MD
-
Osasco、São Paulo、巴西
- 招聘中
- CiTen - Centro Hospital Municipal Antonio Giglio
-
接触:
- Enrico Fortunato, MD
-
首席研究员:
- Enrico Fortunato, MD
-
Presidente Prudente、São Paulo、巴西
- 招聘中
- Hospital Regional de Presidente Prudente
-
接触:
- Luis Felipe Pires, MD
-
首席研究员:
- Luis Felipe Pires, MD
-
Ribeirão Preto、São Paulo、巴西
- 尚未招聘
- Hospital Estadual de Serrana
-
接触:
- Marcos Borges, MD
-
首席研究员:
- Marcos Borges, MD
-
São Paulo、São Paulo、巴西、05403-010
- 招聘中
- HCFMUSP
-
接触:
- Ludhmila Hajjar, MD
-
首席研究员:
- Ludhmila Hajjar, MD
-
São Paulo、São Paulo、巴西、02189-010
- 招聘中
- Hospital Nipo-Brasileiro
-
接触:
- Jose Victor Krasner Schubsky, MD
-
São Paulo、São Paulo、巴西
- 完全的
- Santa Casa de Misericordia de Sao Paulo
-
-
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 招聘中
- University of Chicago
-
接触:
- Jonathan Paul, MD
-
-
Louisiana
-
Jefferson、Louisiana、美国、70121
- 招聘中
- Ochsner Clinic
-
接触:
- Derek Vondehaar, MD
-
-
Maine
-
Portland、Maine、美国、04102
- 招聘中
- Maine Medical Centre
-
接触:
- Daniel Meyer, MD
-
首席研究员:
- Daniel Meyer, MD
-
-
Michigan
-
Dearborn、Michigan、美国、48128
- 完全的
- Henry Ford Health System
-
-
New Jersey
-
Camden、New Jersey、美国、08103
- 招聘中
- Cooper University Health Care
-
接触:
- Adam Green, MD
-
首席研究员:
- Adam Green, MD
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- 招聘中
- Medical College of Wisconsin
-
接触:
- Alisha Sharma, MD
-
首席研究员:
- Alisha Sharma, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patients ≥18 years of age
-
Admitted to hospital for a suspected or confirmed diagnosis of CAP defined by:
- Radiographic evidence of new or worsening infiltrate
- One or more of the following signs and/or symptoms of lower respiratory tract infection
i. New or increased cough or sputum production ii. Fever of > 37.8C or temperature < 36C iii. WBC > 11 x 109/L or < 4 x 109/L c. The primary diagnosis is believed to be CAP as per the attending physician
-
Requires supplemental oxygen to treat hypoxemia (or requires an increased level of supplemental oxygen if on chronic oxygen therapy)
-
Hospital admission anticipated to last ≥72 hours from randomization
Exclusion Criteria:
-
Suspected or confirmed active COVID-19 infection
-
Hospital admission for >72 hours prior to randomization
-
Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment
-
Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
-
Patients for whom the intent is to not use pharmacologic thromboprophylaxis
-
Patients with an independent indication for therapeutic-dose anticoagulation
-
Patients with a contraindication to therapeutic-dose anticoagulation, including:
- Non-traumatic bleeding that requires medical evaluation or hospitalization within 30 days prior to CAP hospital admission
- History of an inherited or acquired bleeding disorder
- Cerebral aneurysm or mass lesions of the central nervous system
- Ischemic stroke within 3 months of hospital admission
- Gastrointestinal bleeding within 3 months of hospital admission
- Platelet count <50 x109/L OR INR >2.0 OR hemoglobin <80 g/L at the time of screening
- Other physician-perceived contraindications to therapeutic anticoagulation
-
History of heparin induced thrombocytopenia (HIT) or other heparin allergy
-
Current or recent (within 7 days of screening) use of dual anti-platelet inhibitors (For example; Aspirin + one of the following; clopidogrel, ticagrelor, prasugrel)
-
Patients in whom imminent death is anticipated
-
Anticipated transfer to another hospital that is not a study site within 72 hours of randomization
-
Enrollment in other interventional trials related to anticoagulation or antiplatelet therapy during current hospitalization
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Therapeutic-Dose Heparin
Participants randomized to the investigational arm will receive a pragmatic strategy of therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first. Participants should start receiving study drug as soon as possible following randomization. |
Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient. Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement. |
|
无干预:Usual Care
Participants randomized to the control arm will receive usual care thromboprophylactic dose anticoagulation according to local practice. To ensure adequate separation between the study groups, the dose of heparin/LMWH used in the usual care arm should not equal more than half of the approved therapeutic dose for that agent according to local VTE treatment protocols. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Ordinal endpoint reflecting survival
大体时间:30 days
|
Survival to hospital discharge without ICU-level organ support. Organ support is defined as receipt of high flow nasal oxygen, invasive or non-invasive mechanical ventilation, vasopressor/inotropic therapy, or extracorporeal life support (ECLS) within an ICU. This outcome reflects disease progression to ICU-level organ failure or the worst possible outcome (death). It was chosen because of its importance to patients, clinicians, and other stakeholders. Given the limited number of ICU beds, reducing the burden of critical illness has important health system capacity implications. |
30 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
全因死亡率
大体时间:30 天、90 天和 180 天
|
30 天、90 天和 180 天
|
|
|
Bleeding events
大体时间:14 days
|
Number of participants with major bleeds as defined by the ISTH definition. |
14 days
|
|
HIT events
大体时间:14 days
|
Number of participants with laboratory confirmed heparin induced thrombocytopenia (HIT) |
14 days
|
|
Thrombotic events
大体时间:30 days and 90 days
|
Number of participants with deep vein thrombosis, pulmonary embolism, systemic arterial thromboembolism, myocardial infarction, or ischemic stroke |
30 days and 90 days
|
|
Invasive mechanical ventilation
大体时间:30 days
|
Ordered categorical endpoint with three possible outcomes based on the worst status of each patient through day 30 following randomization |
30 days
|
|
Hospital-free days
大体时间:30 days, 90 days, and 180 days
|
Days alive outside hospital |
30 days, 90 days, and 180 days
|
|
Health related quality of life
大体时间:30 days, 90 days, and 180 days
|
Using the EQ-5D-5L instrument |
30 days, 90 days, and 180 days
|
|
Health related quality of life
大体时间:30 days, 90 days, and 180 days
|
Using the Clinical Frailty Scale instrument |
30 days, 90 days, and 180 days
|
合作者和调查者
合作者
调查人员
- 首席研究员:Patrick Lawler, MD、University Health Network and McGill University
- 首席研究员:Sylvain Lother, MD、University of Manitoba
- 首席研究员:Alexis Turgeon, MD、L'Universite Laval
- 首席研究员:Ryan Zarychanski, MD、University of Manitoba
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.